Login / Signup

Infliximab Concentrations in Participants with Moderate to Severe COVID-19.

Stephen J BalevicDima DandachiDanielle DixonRichard M W HoetelmansSam BozzetteMatthew W McCarthynull null
Published in: Journal of clinical pharmacology (2023)
Keyphrases
  • coronavirus disease
  • sars cov
  • high intensity
  • early onset
  • ulcerative colitis
  • drug induced